Sales of Julphar Grow by 11%, Profit Grows to AED 117 Million
Dubai, 25 July 2013, Julphar registered sales revenue of AED 696.4 million in the first six months of the year 2013, up 10.5% year-on-year (yoy). Sales during the period were driven by the private market sales which saw a yoy growth of 13.4%.
The company continued to show good operational performance during the period. Gross Profit during the period was AED 412.1 million, up 8.3% yoy. Operating Profit for the period, on the other hand, was AED 126.5 million, up 2.8% yoy. Operating profit margin during the period was a robust 18.2%. Profit for the period was AED 116.9 million, up 5.5% yoy.
Julphar Chairman, HH Sheikh Faisal bin Saqr Al Qasimi commented "The financial figures reflect a successful first half of the year for Julphar. Maintaining stable financial growth and delivering sustainable healthcare is a key priority of the board."
-Ends-
About Julphar
Established in 1980, Julphar is a regional leader in the production and distribution of high quality, affordable pharmaceutical products.
The Julphar manufacturing network consists of twelve world-class production facilities (with further expansion planned) and a reliable logistics network which spans five continents.
Their diverse product portfolio contains over 800 products and targets major therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management.
In 2012, Julphar became the only company in the Middle East to produce the raw material needed to make insulin, through the launch of a division entirely dedicated to Diabetes.
© Press Release 2013
